Nutriband Inc. Pioneers Abuse-Deterrent Drug Delivery with Innovative Transdermal Patches
TL;DR
Nutriband Inc. is leading in abuse-deterrent drug delivery with AVERSA Fentanyl and Buprenorphine, offering investors a competitive edge in a market with potential sales up to $200 million.
Nutriband's AVERSA technology integrates transdermal innovation with abuse-deterrent science, creating patches that prevent misuse and accidental exposure of potent drugs like fentanyl and buprenorphine.
Nutriband's development of abuse-deterrent patches like AVERSA Fentanyl and Buprenorphine aims to significantly reduce opioid abuse and accidental exposure, enhancing public health safety.
Discover Nutriband's groundbreaking AVERSA technology, transforming transdermal patches into safer alternatives by deterring abuse and misuse of powerful opioids.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. (NASDAQ: NTRB) is making significant strides in the pharmaceutical industry with its innovative abuse-deterrent drug delivery system. The company's flagship products, AVERSA Fentanyl and AVERSA Buprenorphine, are at the forefront of addressing the critical public health issue of opioid abuse and misuse. These transdermal patches incorporate Nutriband's proprietary AVERSA technology, designed to deter abuse and reduce the risk of accidental exposure, marking a potential turning point in opioid pain management.
The AVERSA Fentanyl patch, poised to be the world's first opioid patch with abuse-deterrent properties, has the potential to generate peak annual U.S. sales of $80 to $200 million. Similarly, AVERSA Buprenorphine, upon approval, is projected to achieve peak U.S. sales between $70 and $130 million. These projections underscore the significant market demand and the urgent need for safer opioid delivery systems. Nutriband's scalable platform not only supports these two candidates but also paves the way for future innovations in transdermal pharmaceutical products.
Global patent protection for Nutriband's technology is on track, further solidifying the company's position as a leader in the development of abuse-deterrent transdermal patches. This advancement represents a critical step forward in combating the opioid crisis, offering a safer alternative for patients requiring opioid therapy while addressing the widespread issues of abuse, misuse, and accidental exposure.
The implications of Nutriband's innovations extend beyond the pharmaceutical industry, offering hope for a reduction in opioid-related deaths and injuries. By providing a solution that deters abuse without compromising the efficacy of the medication, Nutriband is contributing to a broader public health effort to manage pain safely and effectively. The development of AVERSA Fentanyl and AVERSA Buprenorphine could set a new standard in opioid prescription practices, emphasizing safety and abuse deterrence.
Curated from InvestorBrandNetwork (IBN)
